Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594510 | 1.00 | ELANE (0.54) | ELANENAMPTBIRC2CTSKACE | |
| SCHEMBL4408069 | 0.92 | ELANE (0.52) | ELANENAMPTBIRC2CTSK | |
| SCHEMBL13594509 | 0.92 | ELANE (0.52) | ELANENAMPTBIRC2CTSK | |
| SCHEMBL8038455 | 0.91 | ELANE (0.48) | ELANEBIRC2ACEDPP8DPP9 | |
| SCHEMBL13223231 | 0.85 | ELANE (0.44) | ELANECTSK | |
| SCHEMBL13594417 | 0.85 | ELANE (0.54) | ELANENAMPTBIRC2CTSK | |
| SCHEMBL13594418 | 0.85 | ELANE (0.53) | ELANENAMPTBIRC2CTSK | |
| SCHEMBL8199419 | 0.85 | ELANE (0.42) | ELANENAMPTCTSKACEDPP8 | |
| SCHEMBL13573853 | 0.85 | ELANE (0.42) | ELANENAMPTCTSKACEDPP8 | |
| SCHEMBL13594430 | 0.84 | ELANE (0.54) | ELANEBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-2029153-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007089618-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, CTSC, PEPD | ELANE 208/4885NAMPT 487/4885BIRC2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.